Wave Life Sciences Ltd (WVE) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Wave Life Sciences Ltd $2.17, price $3.95, upside -45.1%, quality 17 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Wave Life Sciences Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $1.23 – $21.31 · fair‑value band $1.43 – $2.71 · the $3.95 price screens above the $2.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Wave Life Sciences in your weekly email
Every Wednesday you see whether Wave Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Show more
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Stock analysis
Wave Life Sciences Ltd (WVE) currently trades at $3.95, while our model-based Fair Value estimate is $2.17, implying the stock looks roughly 82.2% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $1.43 (bear) to $2.71 (bull), the price of $3.95 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Wave Life Sciences Ltd reported revenue of $42.7M in FY2025 versus $41.0M in FY2021, a compound +1.1%/yr. Reported net income was −$204M in FY2025.
Key figures
Market cap $798M · P/S ratio 12.8 · EPS (TTM) $−1.08 · Return on equity −67.4% · Return on assets (EBIT) −52.5% · Operating margin −3,248% · Revenue (TTM) $65.4M · Revenue growth (YoY) −73.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (medium confidence).
What moves the price
The share trades about 81% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −45%, WVE screens richer than that median.
Fair Value models
Bear $1.43Fair Value $2.17Bull $2.71
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−60.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Start year 2020 (pandemic). Over 10 years: +75.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+75.7%
’15
’16
’17
’18
’19
’20
’21
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−763.9% (2020) → −504.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score24 · Bottom 25%
Fair Value upside−45% · Above median
Profitability
Return on assets−34% · Bottom 25%
Growth and dividend
Revenue growth−74% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.52× · Cheaper than median
P/S (TTM)12.21× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Wave Life Sciences Ltd Fair Value". https://www.fairvalue-calculator.com/stock/WVE
Frequently asked questions
Is Wave Life Sciences Ltd (WVE) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $2.17 versus a price of $3.95, about −45% upside (overvalued).
What is the fair value of WVE?
Our model-based fair value for Wave Life Sciences Ltd is $2.17 (as of Sep 23, 2026), built from audited fundamentals. The current price: $3.95.
What is the quality score of WVE?
Wave Life Sciences Ltd has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Wave Life Sciences Ltd (WVE)?
Our model-based price target is the fair value of $2.17 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $1.43, optimistic scenario $2.71. It is a calculation from audited fundamentals, not an analyst target.
What is the Wave Life Sciences Ltd stock forecast for 2026?
Our models put fair value at $2.17, about −45% upside versus a price of $3.95 (overvalued). Cautious scenario $1.43, optimistic scenario $2.71. The calculation is refreshed regularly with new filings.
What is the revenue of Wave Life Sciences Ltd (WVE)?
Wave Life Sciences Ltd reported trailing-twelve-month revenue of about $65.4M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Wave Life Sciences Ltd (WVE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Wave Life Sciences Ltd it is $2.17 per share (as of Sep 23, 2026), against a price of $3.95. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Wave Life Sciences Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, WVE trades above its calculated fair value: price $3.95, fair value $2.17, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of WVE?
No. The price is what the market pays today ($3.95); the fair value is what the company's own numbers justify ($2.17). For Wave Life Sciences Ltd the two are $1.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is Wave Life Sciences Ltd worth?
The market values Wave Life Sciences Ltd at about $798M (market capitalisation, as of Sep 23, 2026). Per share that is $3.95; our models calculate a fair value of $2.17 per share.
What do the bullish and bearish scenarios say about WVE?
Our models span a range for Wave Life Sciences Ltd: cautious scenario $1.43, base $2.17, optimistic $2.71 per share (as of Sep 23, 2026, price $3.95). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Wave Life Sciences Ltd (WVE)?
Balance-sheet figures for Wave Life Sciences Ltd (as of Sep 23, 2026): return on equity −67.4%. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is WVE from its 52-week high?
Wave Life Sciences Ltd trades at $3.95, about 81% below its 52-week high of $21.31 and at the low of $3.95 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $2.17 is for.
Which stocks are comparable to Wave Life Sciences Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Wave Life Sciences Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price $3.95, calculated fair value $2.17 (−45%), Quality Score 17/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of WVE calculated?
We run Wave Life Sciences Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.17, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Wave Life Sciences Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Wave Life Sciences Ltd (WVE)?
The closing price on Sep 23, 2026 was $3.95. Our model-based fair value is $2.17, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Wave Life Sciences Ltd right now?
The price sits above even our optimistic bull case ($2.71). The favourable scenario is already priced in. Weak quality (17/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.43 to $2.71) leaves room in how you read the outcome.
Key figures of Wave Life Sciences Ltd
How large is the market capitalisation of Wave Life Sciences Ltd (WVE)?
The market capitalisation of Wave Life Sciences Ltd is $798M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Wave Life Sciences Ltd (WVE)?
The price-to-sales ratio of Wave Life Sciences Ltd is 12.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Wave Life Sciences Ltd (WVE)?
Earnings per share at Wave Life Sciences Ltd are $−1.08. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Wave Life Sciences Ltd (WVE)?
The return on equity (ROE) of Wave Life Sciences Ltd is −67.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Wave Life Sciences Ltd (WVE)?
On an EBIT basis the return on assets of Wave Life Sciences Ltd is −52.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Wave Life Sciences Ltd (WVE)?
The operating margin of Wave Life Sciences Ltd is −3,248% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Wave Life Sciences Ltd (WVE)?
Revenue at Wave Life Sciences Ltd is growing −73.9% versus a year earlier (3y avg +127%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Wave Life Sciences Ltd (WVE) generate?
The free cash flow of Wave Life Sciences Ltd is −$187M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Wave Life Sciences Ltd (WVE) hold?
Wave Life Sciences Ltd holds more cash than debt, $584M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Wave Life Sciences Ltd in the live analysis
One click puts Wave Life Sciences Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026